Sai Parenteral’s IPO Day 3 is turning out to be a quiet close rather than a frenzy. The issue, which opened on March 24, is set to close today, March 26. But the numbers so far tell a cautious story.
From a market sentiment lens, this IPO hasn’t yet seen aggressive participation. Investors seem to be taking a measured approach, watching closely rather than rushing in.
Market Performance: Sai Parenteral’s IPO Day 3 Subscription Update
As of 10:20 AM on Day 3, the overall response remains muted.
- Total Subscription: 0.43x
- Total Bids: 32.01 lakh shares
- Total Shares on Offer: 75.22 lakh
Category-wise participation shows a mixed trend:
- Retail Investors: 0.06x
- Non-Institutional Investors (NII): 1.05x
- Qualified Institutional Buyers (QIB): 0.60x
The retail segment is still largely on the sidelines. Meanwhile, NII participation has just crossed the full subscription mark, offering some support to the issue.
What’s Driving the Slow Response?
Sai Parenteral’s IPO Day 3 reflects a broader market mood—investors are becoming selective.
There’s no panic. No rush either.
Instead, participation is coming in phases. Institutional and high-net-worth investors are showing relatively better interest, while retail investors remain cautious till the last day.
This kind of trend is not unusual in current market conditions, where capital is moving carefully and investors are focusing more on clarity and timing.
Sai Parenteral’s IPO Key Details You Should Know
Here’s a quick snapshot of the issue structure:
- IPO Size: ₹409 crore
- Fresh Issue: 0.73 crore shares (₹285 crore)
- Offer for Sale (OFS): 0.32 crore shares (₹123.79 crore)
- Anchor Investment Raised: ₹122.6 crore
Price Band
- ₹372 to ₹392 per share
Lot Size
- 38 shares per lot
- Minimum Investment (Retail): ₹14,896 (at upper band)
Timeline
- IPO Opened: March 24
- IPO Closes: March 26
- Allotment Date: March 30 (expected)
- Listing Date: April 2 (tentative)
How the IPO Proceeds Will Be Used?
The company has clearly outlined where the money will go. This gives a fair idea of its near-term priorities.
- ₹111 crore for capacity expansion and facility upgrades
- ₹18 crore for setting up a new R&D centre
- ₹14.30 crore towards debt repayment
- Remaining funds for general corporate purposes
This allocation shows a focus on scaling operations and strengthening infrastructure.
Company Details: What Sai Parenteral’s Does?
Sai Parenteral’s operates in the pharmaceutical formulations space. It’s not just a manufacturing company—it has a broader presence across the value chain.
The company is involved in:
- Research and development
- Manufacturing of formulations
- Contract development and manufacturing (CDMO)
Its presence spans both domestic and international markets.
Product Portfolio Covers
- Cardiovascular treatments
- Neuropsychiatry
- Anti-diabetic drugs
- Respiratory care
- Antibiotics
- Gastroenterology
- Vitamins, minerals, and supplements (VMS)
- Pain management (analgesics)
- Dermatology
Dosage Forms Offered
- Injectables
- Tablets
- Capsules
- Liquid orals
- Ointments
This diversified product mix gives the company a wide operational base across multiple therapeutic areas.
Investor Participation Structure
The IPO follows the standard book-building process.
- Up to 50% reserved for QIBs
- Not more than 15% for NIIs
- Around 35% allocated to retail investors
This distribution is designed to balance institutional and retail participation.
What Stands Out on Sai Parenteral’s IPO Day 3?
There are a few clear takeaways from Day 3:
- Overall demand is still below full subscription
- Retail participation remains very low at 0.06x
- NII category has shown relatively stronger interest
- Institutional interest is moderate but not aggressive
The final hours of Sai Parenteral’s IPO Day 3 will be crucial. Historically, many IPOs see last-minute bids, especially from institutional players.
Summary: Sai Parenteral’s IPO Day 3 at a Glance
Sai Parenteral’s IPO Day 3 is shaping up as a slow-moving but closely watched issue.
- Subscription stands at 0.43x so far
- Retail investors are still on the sidelines
- NII participation offers some support
- The company is focused on expansion, R&D, and debt reduction
As the IPO heads into its final hours, all eyes remain on whether participation picks up momentum or stays measured till the close.
In markets like these, the tone is clear—investors are not chasing every IPO. They are choosing carefully.
